Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Not Applicable
- Conditions
- Chronic Myeloid Leukemia
- Registration Number
- JPRN-UMIN000006358
- Lead Sponsor
- Epidemiological and Clinical Research Information Network(ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Previous treatment with TKI or INF
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A Major molecular response(MMR)rate at 12 months after the intiation of Dasatinib treatment
- Secondary Outcome Measures
Name Time Method